Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C14H19N5O2 |
Molar mass | 289.339 g·mol−1 |
3D model (JSmol) | |
| |
|
Etazolate (SQ-20,009, EHT-0202) is an anxiolytic drug which is a pyrazolopyridine derivative and has unique pharmacological properties.[1][2][3] It acts as a positive allosteric modulator of the GABAA receptor at the barbiturate binding site,[4][5][6][7] as an adenosine antagonist of the A1 and A2 subtypes,[8] and as a phosphodiesterase inhibitor selective for the PDE4 isoform.[9][10][11] It is currently in clinical trials for the treatment of Alzheimer's disease.[12]
Receptor (ligands) |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Transporter (blockers) |
| ||||||||||
Enzyme (inhibitors) |
| ||||||||||
Others | |||||||||||
See also: Receptor/signaling modulators |